Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).
|Alliance Global Partners||James Molloy|
|B. Riley FBR||David Buck|
|Brookline Capital Markets||Kumaraguru Raja|
|Dawson James||Bob Wasserman|
|Roth Capital Partners||Scott R. Henry, CFA|
|Zacks Small-Cap Research||David Bautz, PhD|
Tonix Pharmaceuticals Holding Corp. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Tonix Pharmaceuticals Holding Corp.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Tonix Pharmaceuticals Holding Corp. or its management. Tonix Pharmaceuticals Holding Corp. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.